Background

1. Since publication in 2007 of this set of local guidelines on postexposure management following occupational exposure to blood-borne pathogens, new data and international guidelines\(^1\) have emerged in regard to the use of HIV postexposure prophylaxis and schedule of subsequent serological testing. Although the basic principles of management remain largely unchanged, the Scientific Committee on AIDS and STI (SCAS), and the Infection Control Branch of the Centre for Health Protection consider it necessary to add the corresponding updates to these guidelines.

Guiding principles

2. As with the previous document, this set of revised guidelines is recommended according to the following principles:

   (a) An integrated approach is taken by considering collectively the most important bloodborne infections, i.e. hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) (Annex I).

   (b) Risk assessment and counselling constitute the basis of postexposure management which lead to specific options of postexposure prophylaxis (PEP) when appropriate. As such, case-by-case evaluation is crucial.

   (c) Local perspectives as well as scientific evidence and international developments were taken into account in putting forth the recommendations.

Blood-borne infections and their transmission risks in the health care setting

3. HBV infection is still endemic in Hong Kong, although seroprevalence of HBV surface antigen differs widely among major segments of the population. For example, it is low at 1.1% in new blood donors, but reaches 7.4% in antenatal mothers.\(^2\) Up to 25% of HBsAg carriers may


eventually die of chronic liver diseases, principally hepatocellular carcinoma and cirrhosis.\(^3\) The risk of contracting HBV infection through occupational exposure ranges from 18% to 30%, depending on the type of exposure, the body fluid involved and the infectivity of the source.\(^4\) Specifically, percutaneous injuries with hollow-bored, blood-filled needles from a patient positive with HBeAg carry the highest risk of infection at 37-62%.\(^5\)

4. Between 70 and 80% of people infected with HCV results in chronicity, and a significant proportion of chronic HCV infection results in chronic hepatitis, cirrhosis and hepatocellular carcinoma in 10 to 30 years of time.\(^6\) Prevalence of anti-HCV positivity in new blood donors was below 0.1% in the last decade and it was estimated that some 0.2-0.3% of the population have been infected.\(^7\) HCV is not transmitted as efficiently as HBV. The estimated risk of contracting hepatitis C through needlestick injury involving HCV-infected blood is 1.8% (range 0.7-7%).\(^8\) In a meta-analysis, the risk of transmission was shown to be greater if the source was HCV RNA positive.\(^9\)

5. HIV infection has also been reported to occur in the health care setting. By December 2010, 57 confirmed and 143 possible cases of HIV transmission via occupational exposure had been reported to the US CDC.\(^10\) The average risks of HIV transmission after percutaneous and mucocutaneous exposure to HIV-infected blood were estimated to be 0.3% and 0.09% respectively. In Hong Kong, the prevalence of HIV in the adult population is <0.1%.

6. The prevention of HBV, HCV and HIV transmission in the health care setting depends on the practice of infection control measures based on the principles of standard precautions, provision of personal protective equipment and safety devices, and implementation of safer procedure, e.g. avoidance of needle recapping and sharps disposal in designated containers. The details of infection control practice, however, fall outside the scope of this document. Management after exposure occurs involves provision of first aid, reporting, risk assessment, counselling and additional procedures specific to individual pathogens implicated (Annex I). It is important that those responsible for management should familiarise themselves with the principles and procedures involved.

**First Aid**

---


7. Immediately following any exposure, whether or not the source is known to pose a risk of infection, the wound should be washed immediately and thoroughly with soap and water. Antiseptics are not necessary as there is no evidence of their efficacy. Wounds should not be sucked. For mucosal contact, such as spillage into the conjunctivae, the exposed part should also be washed immediately and liberally with clean running water. The exposed HCW should then seek medical advice for proper wound care and post-exposure management.

**Reporting**

8. The institution should ensure that a mechanism is in place and made known to all HCW to facilitate reporting and management of sharps injury and mucosal exposure in the occupational setting. Clear documentation and investigation of the circumstances of exposure are necessary. In addition, a surveillance system of exposure events should be set up with a view to avoidance of similar incidents. In this endeavour, however, safeguard of confidentiality is of the utmost importance since such exposures often occur in the presence of co-workers.

**Counselling**

9. Until infection is ruled out, health care staff potentially exposed to HBV, HCV, or HIV infected blood should refrain from donating blood, plasma, organs, tissue or semen. Safer sex with condom is advisable.

**Management of accidental exposure to HBV**

10. The management of an incident of accidental exposure to HBV involves proper risk assessment, counselling tailored to the needs of individual client, and the prescription of postexposure prophylaxis as appropriate.

11. As a rule, for the best protection, all health care staff with potential risk of exposure to blood and body fluids are advised to receive hepatitis B vaccination as soon as possible for their own safety. Subjects with anti-HBs titre ≥ 10 mIU/mL 1-4 months after vaccine completion are considered as responders. Non-responders are those with no detectable anti-HBs and hypo-responders refer to those whose anti-HBs titre are between 0-10 mIU/mL. Both non- and hypo-responders should complete a second 3-dose vaccine series and retested at the completion of the second vaccine series. Non-responders to the initial 3-dose vaccine series have a 41% chance of responding to a second 3-dose series.11

12. Though antibody levels fall gradually over time, those who have mounted an initial response following the 3-dose regimen could achieve effective protection upon a subsequent challenge, regardless of the titre of anti-HBs at the time of exposure. This is referred to as the anamnestic response.

13. The efficacy of hepatitis B immunoglobulin (HBIG) and HBV vaccine for postexposure protection in occupational exposure can be referenced from the scene in perinatal transmission. A single dose of HBIG lowers the infection rate of infants born to HBsAg positive mothers from

---

Continuing Education (iCE) on HIV/AIDS
Special Preventive Programme, Department of Health

92% to 54% at 1 year. With multiple doses, HBIG becomes 70-75% effective. The efficacy of protection is further increased to 85-95% by adding a standard HBV vaccination regimen to HBIG.

The need for HBIG administration and HBV vaccination depends on the exposure, and HBV status of the source and the exposed. (Annex II) Individuals who lack HBsAg and have not previously developed satisfactory immune response to the virus may be susceptible. They could be offered HBIG for immediate protection upon significant exposure to HBV. An individualised approach founded on risk assessment is recommended for the management of a health care worker with unknown response to hepatitis B vaccination, one who has been exposed to an unknown source or a source with unknown hepatitis status. In such circumstances, the HBV status of the source and/or the exposed should be determined where appropriate. The exposed person may be managed as in the case of an injury involving an HBsAg positive source person if the HBV status of the source cannot be ascertained.

Management of accidental exposure to HCV

One principle of HCV post-exposure management is to identify those with acute HCV infection and refer them to specialists for further evaluation. At baseline, blood specimen for HCV antibody should be obtained for both the source (with informed consent) and the exposed. The specimen from the former should be tested, while that from the latter should be kept by the laboratory and stored for at least one year. For the exposed, the test is performed on another specimen obtained at 6 months, and 12 months if the source is HIV-HCV co-infected. If positive, the baseline specimen from the exposed is retrieved for testing to diagnose seroconversion. (Annex III)

If the source person is known to be HCV infected or is an injecting drug user with unknown HCV status, baseline ALT should be considered for the exposed. Furthermore, HCV Ab, ALT and HCV-RNA should be determined between 6 to 8 weeks in order to capture those who develop acute hepatitis. Those who do should be promptly referred to specialists for further evaluation.

Currently, there is no effective vaccine or chemoprophylactic agent for preventing HCV infection after accidental occupational exposure. However, treatment of acute infection (interferon or pegylated interferon, with or without ribavirin) may prevent progression to chronic HCV infection. The sustained virological response may be up to 90% or higher when treatment is started within 12 weeks of symptom onset. Nevertheless, it should be borne in

---

mind that some 26% of patients with acute HCV infection would have spontaneous resolution without treatment.\textsuperscript{18} As of now, the optimal regimen, dose and time to initiate therapy remain undefined. Therefore, patients who have acute hepatitis C should be promptly evaluated by experts in this field.

**Management of accidental exposure to HIV**

18. The issue of PEP should be considered after an exposure that has the potential risk of HIV infection. Initial assessment should include the type of body fluid or substance involved, the route and severity of the exposure and the likelihood of HIV infection in the source patient.

19. Occupational injuries may be divided into: (a) percutaneous exposure (from needles, instruments, bone fragments, human bite with breach of skin, etc); (b) exposure via broken skin (abrasions, cuts, eczema etc); and (c) exposure via mucous membranes including the eye.

20. In addition to blood and visibly bloody body fluids, potentially infectious fluids include cerebrospinal fluid, synovial fluid, pleural, peritoneal fluid, pericardial fluid, and amniotic fluid. Although semen and vaginal secretions are also potentially infectious, these are not normally implicated in the health care setting. Faeces, nasal secretions, saliva, sputum, sweat, tears, urine and vomitus are not considered infectious unless they are visibly bloody.

21. It has been shown that some features of the accident were associated with a higher potential of seroconversion after percutaneous exposure to HIV-infected blood. These included: (a) injury with a device visibly contaminated with the patient’s blood; (b) a procedure involving a needle which has been placed in a vein or artery; (c) deep injury; and (d) exposure from source patients with AIDS or high plasma viral burden.\textsuperscript{19}

22. A person infected with HIV may not be aware of his or her own HIV serostatus. Therefore, the exposed person should always be encouraged to have baseline blood taken for HIV antibody after receiving pre-test counselling and giving consent.

23. If possible and with informed consent, the HIV status of the source person should be assessed. A validated HIV rapid test, such as the OraQuick\textsuperscript{®} test, followed by Western blot for confirmation if positive may be considered. Its role in reducing anxiety of the exposed and avoiding unnecessary antiretroviral prophylaxis has been shown.\textsuperscript{20}

24. Nevertheless, the HIV status of source person is not always obtainable. Therefore, the likelihood of HIV infection has to be estimated based on clinical clues in the setting: (a) HIV prevalence of the community group which the source belongs to (b) HIV-related risk behaviours, e.g. unprotected sex, multiple sex partners, needle-sharing for drug injection; (c) HIV-related illnesses, e.g. *Pneumocystis jiroveci* pneumonia, oral thrush etc.


25. If the source person is HIV-infected and the exposure event constitutes a significant risk of HIV transmission, antiretroviral chemoprophylaxis should be considered. Findings from animal studies suggested that antiretroviral drugs would not be effective if begun more than 72 hours after exposure. Therefore it should be initiated as soon as possible, preferably within 1-2 hours of exposure, and continued for 4 weeks. Delayed initiation after 72 hours may be considered only on an exceptional basis if the likelihood of benefit clearly outweighs the risks inherent in taking antiretroviral medications and the possibility of antiretroviral resistance should transmission occur.

26. A combination of at least three drugs should be used for PEP if indicated. No comparative trial data on efficacy are available for different PEP regimens. As far as nucleoside reverse transcriptase inhibitor (NRTI) is concerned, zidovudine may be the antiretroviral with the most extensive evidence on risk reduction of HIV transmission following occupational exposure. However, recent studies have also supported the use of other NRTIs, such as tenofovir and emtricitabine, as a component of PEP, demonstrating good tolerability and safety.

27. Other than the 2-NRTI backbone, a ‘third’ drug is needed to constitute a PEP regimen. Based on the experience in management of established HIV infection and the relative rarity of primary resistance in Hong Kong, ritonavir-boosted protease inhibitor (PI) is generally preferred. The newly available ritonavir tablet and PI such as darunavir make this option more tolerable and convenient than before.

28. The ‘third’ drug may theoretically be a non-nucleoside reverse transcriptase inhibitor (NNRTI). However, nevirapine is contraindicated for PEP due to an unacceptably high risk of hepatotoxicity in HIV negative subjects. Efavirenz, another commonly used NNRTI in established HIV infection, is also associated with neuropsychiatric effects and with potential teratogenicity in pregnant women. Recently available, the newer NNRTIs including etravirine and rilpivirine are more tolerable. They may be considered as alternatives if available.

29. Recently, the use of integrase inhibitor (II) together with two NRTI has also gained acceptance because of remarkable tolerance and the hitherto low prevalence of primary II resistance.

30. Fixed-dose combination antiretrovirals are more expensive but preferred if available. Table 1 summarises information on the commonly used antiretrovirals. It is noted that antiretroviral therapy is a rapidly changing field and the most updated information should be obtained before prescription. Experts in HIV medicine should be consulted if the source person is suspected to have antiretroviral resistance.

31. Timely assessment and treatment are keys to success of PEP. The Emergency Department is often the first place where an HCW presents after occupational exposure. It is advisable that the Department make a decision on the appropriate starter PEP regimen(s) to stock and devise its own management protocol. Treatment should be started as soon as possible if indicated by a rapid assessment. Early referral is then made for follow up by physicians with more expertise in antiretroviral therapy.

32. Many HCWs who take PEP experience adverse effects and a substantial proportion could not complete the full 4-week course of treatment.\(^{25}\) Therefore, they should be carefully followed. Baseline and serial blood tests are indicated, adverse effects of antiretrovirals are expectantly managed, and counselling and support given to enhance adherence.

33. Follow-up HIV antibody tests should normally be performed at 3 to 6 months. Additional, earlier testing may also be needed to alleviate anxiety or to evaluate possible acute retroviral syndrome. Testing at a longer interval may also be considered, such as to detect delayed HIV seroconversion in those who have become infected with HCV after exposure to a source co-infected with HIV and HCV.

Centre for Health Protection
January 2014

The copyright of this paper belongs to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. Contents of the paper may be freely quoted for educational, training and non-commercial uses provided that acknowledgement be made to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. No part of this paper may be used, modified or reproduced for purposes other than those stated above without prior permission obtained from the Centre.

Flow chart: General algorithm of management of occupational exposure to HBV, HCV and HIV

Occupational exposure

First aid

Reporting

Risk assessment

Exposure evaluation

Source & exposed evaluation

If risk is established, perform baseline blood testing for HBV*, HCV* (see Annex III) and HIV for exposed and source

Choice of postexposure prophylaxis regimen

Follow-up for laboratory testing & clinical assessment

# Testing for HBsAg/Anti-HBs may be omitted if the exposed is known to be a responder to the HBV vaccine or have natural immunity against HBV
* Baseline specimens of exposed are often initially stored, and retrieved for testing when a subsequent specimen tests positive
### Postexposure prophylaxis against HBV infection

**Annex II**

<table>
<thead>
<tr>
<th>I. SOURCE KNOWN</th>
<th>Previously Vaccinated</th>
<th>Unvaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Known Responders</td>
<td>Known Hypo-/ Non-responders</td>
</tr>
<tr>
<td>(a) HBsAg + ve</td>
<td>Nil</td>
<td>HBIG within 24 hours; repeat after 1 month</td>
</tr>
<tr>
<td>(b) HBsAg – ve</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>(c) HBsAg unknown</td>
<td>Nil</td>
<td>Dependent on source HBsAg status</td>
</tr>
</tbody>
</table>

| II. SOURCE UNKNOWN | | |
|---------------------| | as in I(a) |
|                     | as in I(a) | as in I(a) |

**N.B.**

1. Blood should be taken from the source and the exposed person whenever possible and indicated, particularly if the latter has not received hepatitis B vaccination before.
2. Where indicated, one dose of HBIG (dosage as recommended by the manufacturer) should be given within 7 days, preferably within 24 hours of exposure. Attention is drawn to the need of blood taking before administering HBIG.
3. Hepatitis B vaccination (HB Vac) is offered for (a) health care workers (HCW) who have not received HB vaccination before, and (b) HCW who are hypo-/non-responder to one previous course of HB vaccine. HB Vac is given IM into the deltoid at a dose of 10ug (B-Hepavac II) or 20ug (Engerix-B). The second and the third doses are to be given one and six months afterwards.
4. HBIG and HBV vaccine can be given together but at different sites. If HBIG has been given, the first dose of vaccine can be delayed for up to 1 week after exposure, pending results of serological test. If HB Vac is started, the second dose of HBIG can be omitted unless the HCW is a known hypo-/non-responder.

* For a previously vaccinated person with unknown response, he/she should be tested for anti-HBs
  * no treatment is required if anti-HBs is positive
  * HBIG ± HBV vaccine is offered if anti-HBs is negative
Flow chart: management of accidental exposure to hepatitis C

Risk established for exposure

Source is known HCV positive, or known IDU with unknown HCV status

Baseline HCV Ab*
Baseline HCV Ab* + ALT

6-8 wk: HCV RNA, ALT, HCV Ab

-ve

+ve

6 months: HCV Ab

-ve but if source is HIV +ve

Consider 12 months: HCV Ab

Referral to specialist for further evaluation ± treatment

-ve, negative
+ve, positive

* Baseline specimens are often initially stored and retrieved for testing when a subsequent specimen tests positive
### Table 1: Some commonly used first-line antiretrovirals for HIV PEP

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Antiretrovirals</th>
<th>Dosage</th>
<th>Major adverse effects and precautions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRTI</td>
<td>Combivir (fixed dose combination of zidovudine 300mg + lamivudine 150mg)</td>
<td>1 tab bd</td>
<td>bone marrow suppression (anaemia, neutropaenia); GI intolerance; headache; insomnia; myopathy; lactic acidosis &amp; hepatic steatosis</td>
</tr>
<tr>
<td></td>
<td>Truvada (fixed dose combination of tenofovir 300mg + emtricitabine 200mg)</td>
<td>1 tab qd</td>
<td>GI intolerance; headache; rarely renal insufficiency and Fanconi syndrome; rarely lactic acidosis &amp; hepatic steatosis</td>
</tr>
<tr>
<td>PI</td>
<td>Kaletra® (lopinavir 200 mg + ritonavir 50 mg)</td>
<td>2 tablets bd</td>
<td>GI upset, especially diarrhoea, elevated transaminases; hyperglycaemia; lipid abnormalities, arrhythmia, prolonged QT, risk of drug-drug interaction</td>
</tr>
<tr>
<td></td>
<td>Ritonavir-boosted Atazanvir</td>
<td>Ritonavir 100mg qd, Atazanavir 300mg qd</td>
<td>Indirect hyperbilirubinaemia; nephrolithiasis; hyperglycaemia; GI intolerance; prolonged QT; risk of drug-drug interaction; administer with food; antacid, H2 blockers, and proton pump inhibitors may reduce absorption</td>
</tr>
<tr>
<td></td>
<td>Ritonavir-boosted Darunavir</td>
<td>Ritonavir 100mg qd, Darunavir 800mg qd</td>
<td>GI intolerance; headache; hepatitis; rash; prolonged QT; risk of drug-drug interaction</td>
</tr>
<tr>
<td>II</td>
<td>Raltegravir</td>
<td>400mg bid</td>
<td>Well tolerated; mild GI intolerance; headache; myositis; rash; affected by UGT1A1 inducers such as rifampicin.</td>
</tr>
</tbody>
</table>

General composition of PEP: 2 NRTI + PI or II
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI protease inhibitor; II, integrase inhibitor
* Please also refer to full prescribing information
Test paper - Recommendations on the management and postexposure prophylaxis of needlestick injury or mucosal contact to HIV, HCV and HBV (January 2014)

Expiration Date: 04 January 2016

# CME point / CNE point: 1 / PEM point: 1 (Healthcare related which contributes to the enhancement of professionalism of midwives/nurses)

Please indicate one answer to each question.

Answer these on the answer sheet and make submission by fax to Special Preventive Programme, Department of Health.

Please contact respective authorities directly for CME/CPD accreditation if it is not on listed below.

<table>
<thead>
<tr>
<th>Accreditors</th>
<th>CME Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Health <em>(for practising doctors who are not taking CME programme for specialists)</em></td>
<td>1</td>
</tr>
<tr>
<td>Community Medicine</td>
<td>1</td>
</tr>
<tr>
<td>Dental Surgeons</td>
<td>1</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>1</td>
</tr>
<tr>
<td>Family Physicians</td>
<td>1</td>
</tr>
<tr>
<td>Obstetricians and Gynaecologists</td>
<td>1</td>
</tr>
<tr>
<td>Ophthalmologists</td>
<td>0.5</td>
</tr>
<tr>
<td>Otorhinolaryngologists</td>
<td>1</td>
</tr>
<tr>
<td>Paediatricians</td>
<td>1</td>
</tr>
<tr>
<td>Pathologists</td>
<td>1</td>
</tr>
<tr>
<td>Psychiatrists</td>
<td>1</td>
</tr>
<tr>
<td>Radiologists</td>
<td>1</td>
</tr>
<tr>
<td>Surgeons</td>
<td>1</td>
</tr>
</tbody>
</table>

1. Which of the following is not true about the guiding principles in the management and postexposure prophylaxis of needlestick injury or mucosal contact to HIV, HCV and HBV?
   (a). Risk assessment and counseling are integral part of the management
   (b). An integrated approach should be adopted to assess various blood-borne pathogens, e.g. HIV, HCV
   (c). Both scientific evidence in general and individual specificities are important considerations
   (d). Local perspective such as disease epidemiology is important
   (e). None of the above

2. Which of the following data is not true regarding postexposure management and prophylaxis for hepatitis B?
   (a). Both HBsAg and anti-HBs have to checked at baseline screening of the exposed
   (b). Booster HBV vaccination is recommended to prevent future risk for exposed subjects with positive anti-HBs
   (c). The second dose of HB immunoglobulin (HBIG) when indicated is given 1 month after exposure
   (d). Exposed subjects who are HBsAg positive requires no prophylactic interventions
   (e). None of the above

3. Which of the following is not true regarding the risk of different blood-borne viruses from exposure in general?
   (a). The average risk of being infected with the respective contaminated blood is highest for HCV, followed by HBV and HIV
(b). The risk of HIV transmission from mucosal exposure to HIV contaminated blood is about 0.1%
(c). The risk depends on the efficiency of the virus in causing transmission as well as the prevalence of the virus
(d). Needlestick injury carries the highest risk in most of the clinic practices
(e). None of the above

4. Which of the following is not true for the antiretroviral postexposure prophylaxis (PEP) against HIV?
(a). Zidovudine is the first drug proven to be effective in postexposure prophylaxis
(b). Three drugs are recommended nowadays if HIV PEP is indicated
(c). Other NRTIs such as tenofovir can be used in place of zidovudine
(d). The duration is 6 weeks
(e). Tolerance and adverse effects of the drugs have to be monitored and managed

5. Which of the following is not part of the procedures in the management of possible exposure to blood borne pathogens?
(a). Check blood for baseline screening for the blood borne pathogens
(b). Asses the risks of acquiring the blood borne pathogens through the exposure
(c). Administer prophylaxis if available for specific pathogens automatically
(d). Counsel and recommend precautions as necessary
(e). Do follow up blood screening

6. Which of the following is not true about the third drug to be added to a NRTI backbone (2 drugs) for HIV postexposure prophylaxis?
(a). Boosted protease inhibitor is commonly used
(b). Integrase inhibitor such as raltegravir is recently recommended due to its good tolerance
(c). Nevirapine is an option
(d). Data about newer NNRTIs is limited
(e). None of the above

7. Which of the following is not true about possible exposure to and management regarding HCV infection?
(a). Immunoglobulin is effective in lowering the risk of HCV transmission
(b). HCV prevalence is low in the general population in Hong Kong
(c). If the source is injecting drug user or known HCV positive, liver function test and HCV RNA should be checked at 6-8 weeks post exposure
(d). A prolonged follow up for HCV seroconversion should be considered if the source is HIV infected
(e). Identification of acute hepatitis C after exposure is important for referral to liver specialist for management

8. Which of the following is not true about prevention of blood-borne pathogens in health care settings?
(a). Adoption and practice of standard precautions is of utmost importance
(b). Personal protective equipment should be used as necessary for the patient care procedures, e.g. wearing glove for blood-taking
(c). Reduction of needlestick injury can be achieved by not recapping needles and use safety device, e.g. retractable needle
(d). Proper post-exposure management
(e). None of the above
9. The HIV status or likelihood of having HIV infection in the source patient can be assessed by the following, except?
   (a) HIV prevalence in the community/population the source belongs
   (b) Presence of AIDS-defining diseases or HIV-related conditions
   (c) Presence of HIV related risk behaviours
   (d) External appearance of the source
   (e) All of the above

10. Which of the following is not true about the risk of HIV transmission after a HIV contaminated percutaneous exposure?
   (a) A deep injury is associated with a higher risk
   (b) A device visibly contaminated with blood is associated with a higher risk
   (c) The average risk is about 1%
   (d) Antiretroviral prophylaxis is effective in significantly reducing the risk
   (e) A higher viral load in the source patient is associated with a higher risk